, Tracking Stock Market Picks
Enter Symbol:
Rating: PCRX
Buy $128

Pacira Pharmaceuticals Inc (NASDAQ: PCRX) reiterated to Buy with price target $128 by Canaccord Genuity

Tuesday,  Mar 3, 2015  9:25 AM ET by Kristen Bailey

Canaccord Genuity reiterated Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Buy with price
target $128. Canaccord Genuity rated Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Buy with price target $143 on 02/12/2015, when the price was $114.23.

Pacira Pharmaceuticals, Inc. (Pacira), formerly Pacira, Inc., is the holding company for the Company?s California operating subsidiary of the same name, which it refers to as PPI-California. The Company is a specialty pharmaceutical company focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its product candidate EXPAREL is a long-acting bupivacaine (anesthetic/analgesic) product for postsurgical pain management. EXPAREL provides analgesia for up to 72 hours post-surgery. EXPAREL consists of bupivacaine encapsulated in DepoFoam. DepoFoam, its extended release drug delivery technology, is the basis for its commercial products: DepoCyt(e) and DepoDur, which it manufactures for its commercial partners. Its product portfolio and product candidate pipeline include EXPAREL, DepoCyt, DepoDur, DepoNSAID and DepoMethotrexate.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy